CURRENT UPDATES IN THE DIAGNOSTIC LANDSCAPE AND THERAPEUTIC STRATEGIES FOR ACQUIRED IDIOPATHIC APLASTIC ANEMIA
Main Article Content
Abstract
Acquired idiopathic aplastic anemia (AA) is a rare, life-threatening condition characterized by the immune-mediated destruction of hematopoietic stem cells. It manifests as peripheral blood cytopenia affecting at least two lineages alongside a hypocellular bone marrow. Despite therapeutic advances, clinical practice variations persist regarding diagnosis and optimal management. AA remains a diagnosis of exclusion, focusing on: (i) confirming marrow hypocellularity via aspirate and trephine biopsy; (ii) excluding malignancies, hypocellular myelodysplastic syndrome (hMDS), marrow infiltration, and secondary causes (infections/drugs/chemicals); and (iii) screening for inherited bone marrow failure (IBMF) in younger patients or those with suggestive clinical/family histories.
Recent international guidelines emphasize expanded diagnostic workups before initiating definitive therapy, including flow cytometry for PNH clones, somatic mutation screening (myeloid panels), and telomere length measurement—particularly in severe, very severe, or refractory cases. Early HLA typing is critical for potential transplant candidates.
Treatment rests on two pillars: allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST). Current BSH 2024 and ASH 2026 guidelines state that initial choice depends on disease severity (modified Camitta criteria), biological age, and donor availability. The modern standard IST for severe AA in non-transplant candidates is the triple combination of hATG, cyclosporine and eltrombopag, supported by the phase III RACE trial data. Complication management must be integrated early, focusing on leukodepleted/irradiated blood products, antimicrobial prophylaxis (anti-mold) when ANC < 0.5 × 10⁹/L, and monitoring for iron overload or clonal evolution via periodic cytogenetics.
Key evidence gaps remain in optimizing alternative donor transplants (MUD/haplo), personalized NGS-based strategies, and the long-term safety of TPO-RAs regarding clonal progression and thrombosis.
Keywords
Acquired idiopathic aplastic anemia, inherited bone marrow failure, allogeneic hematopoietic stem cell transplantation (HSCT), immunosuppressive therapy (IST)